MK-8745 is a selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a key role in regulating cortisol levels within tissues. By inhibiting this enzyme, MK-8745 reduces local cortisol production, particularly in metabolic tissues such as liver and adipose tissue. This mechanism has been explored for the treatment of metabolic disorders including type 2 diabetes and obesity, where elevated tissue cortisol activity contributes to insulin resistance and dyslipidemia. It has been investigated in clinical research to assess its potential in improving insulin sensitivity and glucose metabolism. Due to its targeted action, MK-8745 offers a strategy to modulate glucocorticoid activity without systemic suppression of adrenal function, making it a candidate for safer metabolic intervention. Studies have also looked into its effects on cognitive function and liver health, given the role of cortisol in inflammation and metabolic stress.